AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AtriCure excels in 2022, eyes growth in cardiac surgery market

AtriCure's strong performance in 2022 sets the stage for continued growth and profitability.
Focus on technological advancements and clinical trials to drive future revenue growth.
Addressing challenges like slower adoption and macro pressures with strategic planning.
Positioned for success with a robust product portfolio and international growth prospects.

AtriCure reports robust Q1 earnings, eyes growth amid competition

AtriCure's Q1 2023 performance was strong, with revenue growth and a focus on profitability. Challenges include cash burn and potential competition in the cryoSPHERE market. The company's innovative approach and growth projections offer promising opportunities.

AtriCure posts robust Q2 results, eyes international growth opportunities

AtriCure's Q2 performance showcased strong revenue growth, margin improvement, and strategic acquisitions, positioning the company for continued success.
While challenges like ongoing investments and product optimization exist, opportunities in international markets, acquisitions, and cardiac surgery trends offer avenues for future growth.
The company's focus on clinical trials, long-term market opportunities, and maintaining a strong balance sheet underscores its commitment to innovation and sustainable growth.

AtriCure (ATRC) reports robust Q3 earnings, eyes growth opportunities

AtriCure's strong Q3 performance and positive outlook for full year 2023 demonstrate growth potential across key franchises. Challenges include market transitions impacting pain management growth and the need to adapt to evolving market dynamics. Opportunities lie in new product launches, clinical trials, and market expansion strategies.

AtriCure reports robust Q4 growth, eyes new products and market opportunities

AtriCure's strong financial performance in Q4 2023 and expectations of 15-17% revenue growth in 2024 showcase sustained momentum.
The company's focus on innovation, product adoption, and market opportunities positions it well for future expansion and impact.
Balancing challenges like product development and market dynamics with pricing strength and operational efficiency will be key for continued success.

AtriCure excels in Q1 2024, eyes global impact with innovations

AtriCure's strong start in 2024 driven by revenue and EBITDA growth.
Focus on innovation, clinical trials, and international expansion.
Challenges include product adoption and R&D investment balance.
Opportunities lie in market leadership, new product launches, and global trials.

AtriCure posts strong Q2 results, eyes EU expansion and trial completion

AtriCure's Q2 2024 performance reflects robust revenue growth and positive EBITDA, driven by key franchise expansions and clinical trials.
While facing challenges such as increased operating expenses and a loss per share, the company maintains a focus on innovation and growth opportunities.
Revised full-year guidance and strategic product launches position AtriCure for continued growth and market leadership in the medical device sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference. AtriCure's management is scheduled to present on Tuesday, March 16, 2021, at 1:10 p.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “

AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2020 Results - Earnings Call Transcript

Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimate of ($0.28).

AtriCure: Q4 Earnings Insights

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. “Despite challenges posed in 2020 as a result of the pandemic, we made meaningful progress across our business with our strategic initiatives,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “Looking ahead to 2021 and beyond, we a

AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

On Tuesday, February 23, AtriCure (NASDAQ:ATRC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview: AtriCure

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10th Annual Global Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, February 24, 2021, at 8:00 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by vi

AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 23, 2021 to discuss its fourth quarter and full year 2020 financial results. The call may be accessed through an operator

AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020. “We are pleased with our fourth quarter and full-year results which reflect the resiliency and strength of our team, as well as the overarching unmet need in our core markets. COVID-19 continues to impact our revenue as procedure volumes remain b

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for cryo nerve block (cryoNB) therapy to include the treatment of adolescent patients (12-21 years of age). The cryoICE® and cryoSPHERE™ cryoablation probes are designed to temporarily block pain by ablati

AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy

AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference being held virtually. AtriCure's management is scheduled to present on Monday, January 11, 2021, at 10:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visi

AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday December 3, 2020 A link to the fireside chat presentation will be available on the “Investors” section of the Company's website at https://ir.atric

AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2020 financial results. “We are pleased with our third quarter performance and the improving trajectory of our business, which reflect the commitment of our team and underlying demand in our core markets,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are continuing to

AtriCure Reports Third Quarter 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for

AtriCure to Announce Third Quarter 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference being held virtually.

AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021.

AtriCure Announces Angie Wirick as Chief Financial Officer

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.

Recap: AtriCure Q2 Earnings

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.

AtriCure Reports Second Quarter 2020 Financial Results

AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2019 Results - Earnings Call Transcript

AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.

AtriCure Enters Overbought Territory

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript

News for AtriCure Stock (ATRC)